Merck’s Keytruda (pembrolizumab) Receives EC’s Approval as Adjuvant Treatment for Non-Small Cell Lung Cancer
Shots:
- The EC has approved Keytruda as a monotx. for the adjuvant treatment of adults with NSCLC who are at high risk of recurrence following complete resection & Pt-based CT
- The approval was based on the P-III trial (KEYNOTE-091) evaluating Keytruda (200mg, IV, q3w for 1yr.) vs PBO (IV, q3w for 1yr.) in a ratio (1:1) in 1177 patients. The study was sponsored by Merck & conducted in collaboration with EORTC and the ETOP
- The results showed an improvement in DFS in patients who received adjuvant CT at a median follow-up time of 46.7mos., 24% reduction in risk of disease recurrence or death. At an earlier prespecified interim analysis, improvement in DFS in the overall population with a median follow-up of 32.4mos. who are at high risk of recurrence, II or IIIA
Ref: Businesswire | Image: Merck
Related News:- Merck Reports P-III Trial (KEYNOTE-671) Results of Keytruda for Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
